Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
hMN14 · 3 trials · 9 indications
| Name | Type | Description |
|---|---|---|
| hMN14 (labetuzumab) | DRUG | - |
Disease Characteristics: * Histologic or cytologic diagnosis or either, colonic, rectal, or breast carcinoma * Measurable lesion diagnosed by CT scan * Recurrent/metastatic disease considered surgically unresectable. Prior/Concurrent Therapy: * Chemotherapy: Patients who either have failed at lea...
Top 20 of 77 competitors
hMN14 is an investigational small molecule being studied for the treatment of colorectal cancer and pancreatic neoplasms. It is in Phase 1 clinical development and is not yet approved by the FDA. Clinical trials have evaluated its safety in patients with these cancers.
hMN14 is being developed by Gilead Sciences, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol GILD. The drug is currently in Phase 1 clinical trials for oncology indications.
hMN14 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. All completed trials for hMN14 were Phase 1 safety studies in patients with colorectal cancer or pancreatic neoplasms.
hMN14 has been studied in three completed Phase 1 trials: NCT00040599 in colorectal cancer, NCT00041639 in pancreatic cancer, and NCT00041652 in colorectal or breast cancer. These trials enrolled a total of 177 patients across the United States and Europe.
Yes, hMN14 is the same compound as 90Y-hMN14, which is the radiolabeled form used in some trials. The drug is also referred to as labetuzumab in scientific literature, though this name is not used in the clinical trial records.